H.R. 2430: FDA Reauthorization Act of 2017
CBO Score
$-59,000,000
Documentation
Date of Report
Tue July 11th, 2017
CBO Report Details
Legislation Details
115th Congress
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Sponsor: Rep. Greg Walden — R — OR
This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for brand name drugs. User fees are eliminated for supplemental new drug applications and drug manufactu...
JOIN US!
Sign up below to receive updates when your Members of Congress vote for new spending increases or cuts.
Lost your Password?
Don't be sad- we've got your back. Just enter your email below and instructions on resetting your password will be sent to you.
×